| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRUS | Common Shares, (euro)0.09 nominal value per share | Sale | -$14.6M | -531K | -19.69% | $27.53 | 2.17M | Oct 7, 2021 | Direct | F1, F2 |
| transaction | MRUS | Common Shares, (euro)0.09 nominal value per share | Sale | -$2.22M | -80K | -3.69% | $27.79 | 2.09M | Oct 8, 2021 | Direct | F1, F2 |
| transaction | MRUS | Common Shares, (euro)0.09 nominal value per share | Sale | -$10.6M | -385K | -19.6% | $27.53 | 1.58M | Oct 7, 2021 | Direct | F1, F3 |
| transaction | MRUS | Common Shares, (euro)0.09 nominal value per share | Sale | -$1.62M | -58.3K | -3.69% | $27.79 | 1.52M | Oct 8, 2021 | Direct | F1, F3 |
| transaction | MRUS | Common Shares, (euro)0.09 nominal value per share | Sale | -$1.91M | -69.5K | -22.34% | $27.53 | 242K | Oct 7, 2021 | Direct | F1, F4 |
| transaction | MRUS | Common Shares, (euro)0.09 nominal value per share | Sale | -$248K | -8.93K | -3.69% | $27.79 | 233K | Oct 8, 2021 | Direct | F1, F4 |
Bvf Partners L P/Il is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the Issuer's outstanding shares of Common Shares, (euro)0.09 nominal value per share of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. |
| F2 | Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. |
| F3 | Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. |
| F4 | Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. |